SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Lynch R)
 

Sökning: WFRF:(Lynch R) > (2005-2009) > Reproductive risk f...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004788naa a2200481 4500
001oai:lup.lub.lu.se:8f89836f-951f-4493-948a-d66dfb6cbbf2
003SwePub
008160401s2007 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/11385642 URI
0247 a https://doi.org/10.1016/S1470-2045(06)70983-42 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a McLaughlin, John R4 aut
2451 0a Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study
264 1c 2007
520 a BACKGROUND: Several of the known risk factors for ovarian cancer are thought to act through their effects on ovulation and the menstrual cycle, such as parity, breastfeeding, and use of oral contraceptives. We aimed to assess the effect of these three risk factors, and of tubal ligation, on the risk of ovarian cancer in women who carry a mutation in the BRCA1 or BRCA2 genes. METHODS: We did a matched case-control study in women who were found to carry a pathogenetic mutation in BRCA1 or BRCA2. Participants were derived from a population-based study of ovarian cancer in Ontario, Canada, and from an international registry of mutation carriers based in Toronto, ON, Canada. All participants completed a written questionnaire that detailed their reproductive history. Women with invasive ovarian cancer and controls were matched on year of birth, country of residence, mutation (BRCA1 or BRCA2), and history of breast cancer. The odds ratios and 95% CI for ovarian cancer were estimated with respect to use of oral contraceptives, parity, breastfeeding, and tubal ligation. FINDINGS: Questionnaires were completed by 799 women with a history of invasive ovarian cancer (670 with BRCA1 mutations, 128 with BRCA2 mutations, and one with a mutation in both genes), and controls were 2424 women without ovarian cancer (2043 with BRCA1 mutations, 380 with BRCA2 mutations, and one with a mutation in both genes). Use of oral contraceptives reduced the risk of ovarian cancer in carriers of BRCA1 mutations (odds ratio 0.56 [95% CI 0.45-0.71]; p<0.0001) and carriers of BRCA2 mutations (0.39 [0.23-0.66]; p=0.0004). Parity was associated with a reduced risk for carriers of BRCA1 mutations (0.67 [0.46-0.96]; p=0.03), but with an increased risk for those with BRCA2 mutations (2.74 [1.18-6.41]; p=0.02). Breastfeeding was associated with a reduced risk for carriers of BRCA1 mutations (0.74 [0.56-0.97]; p=0.03). An effect of similar magnitude was seen for carriers of BRCA2 mutations (0.72 [0.41-1.29]; p=0.27), but this was not statistically significant. The association with tubal ligation was not significant for carriers of BRCA1 mutations (0.80 [0.59-1.08]; p=0.15), or for carriers of BRCA2 mutations (0.63 [0.34-1.15]; p=0.13). INTERPRETATION: Oral contraceptives could be used as a means to prevent ovarian cancer in carriers of BRCA1 and BRCA2 mutations. The possible adverse effect of parity on ovarian-cancer risk in women with a BRCA2 mutation needs further study.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Risch, Harvey A4 aut
7001 a Lubinski, Jan4 aut
7001 a Moller, Pal4 aut
7001 a Ghadirian, Parviz4 aut
7001 a Lynch, Henry4 aut
7001 a Karlan, Beth4 aut
7001 a Fishman, David4 aut
7001 a Rosen, Barry4 aut
7001 a Neuhausen, Susan L4 aut
7001 a Offit, Kenneth4 aut
7001 a Kauff, Noah4 aut
7001 a Domchek, Susan4 aut
7001 a Tung, Nadine4 aut
7001 a Friedman, Eitan4 aut
7001 a Foulkes, William4 aut
7001 a Olsson, Håkanu Lund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumörmikromiljö,Institutionen för kliniska vetenskaper, Lund,Bröstcancer-genetik,Institutionen för kliniska vetenskaper, Lund,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Tumor microenvironment,Department of Clinical Sciences, Lund,Breastcancer-genetics,Department of Clinical Sciences, Lund4 aut0 (Swepub:lu)onk-hol
7001 a Hereditary Ovarian Cancer Clinical Study Group, and4 aut
7102 a Medicinsk onkologib Sektion I4 org
7730 t The Lancet Oncologyg 8:1, s. 26-34q 8:1<26-34x 1474-5488
8564 u http://dx.doi.org/10.1016/S1470-2045(06)70983-4y FULLTEXT
8564 8u https://lup.lub.lu.se/record/1138564
8564 8u https://doi.org/10.1016/S1470-2045(06)70983-4

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy